Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Genuis, and R
Retatrutide remains an investigational medication undergoing Phase 3 clinical trials and has not yet received FDA approval
Anticipated prescribing criteria for Retatrutide will likely mirror current obesity medication guidelines with some potential adjustments based on the medication specific benefits
Weeks 17 through 20: tirzepatide 12.5 mg This dose is available for patients who need additional weight loss support and have tolerated lower doses well
US$ 26.15
US$ 21.65
US$ 28.38
US$ 20.55
